Data from a large prospective study identified male and older patients as being more likely to develop CIP and 34% of cases ...

Long-term NATALEE data show adjuvant ribociclib plus an aromatase inhibitor improves invasive disease–free survival vs AI ...

Data from NIAGARA supported the FDA’s approval of neoadjuvant durvalumab in combination with gemcitabine and cisplatin, ...

A preliminary analysis of patient-reported outcomes for emotional functioning (EF) in patients with solid tumors revealed ...

The FDA has granted approval to adjuvant cemiplimab treatment for patients with high-risk cutaneous squamous cell carcinoma ...

On this episode of Onc Nurse On Call, Kristin Daly, MSN, ANP-BC, AOCNP, discusses practical cancer care strategies in the age ...

Chemo-induced myelosuppression can affect patients’ ability to do daily tasks, and management varies by patient, treatment ...

Jackson, the administrative director of advanced practice at the Vanderbilt-Ingram Cancer Centers in Franklin and Nashville, ...

A network to connect patients with unused medications with patients in need brought $18 million of free cancer medication ...

Panelists discuss how the subcutaneous nivolumab data demonstrate reassuring safety with minimal grade 3/4 events, how ...

Panelists discuss how the phase 3 MK-3475-877 trial findings demonstrated subcutaneous pembrolizumab’s pharmacokinetic comparability to intravenous (IV) formulation with similar efficacy (45% vs 42% ...